Rhabdomyosarcoma

Overview

4.4 out of 5 (5 Reviews)

Credits

1.50

Post Assessment Questions

9

Start Date

1 Sep 2023

Last Review Date

12 Feb 2024

Expiration Date

31 Aug 2026

Estimated Time To Finish

90 Minutes

Start This Activity
 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Rhabdomyosarcoma (RMS) is a malignant soft tissue sarcoma that is believed to originate from primitive mesenchymal cells that typically differentiate into skeletal tissue. However, these tumors can also arise in other types of tissue and any anatomic area. RMS is the most common soft tissue sarcoma diagnosed in children; only 1% to 2% of these cancers are found in adults. The etiology and risk factors remain largely unknown. Most cases of rhabdomyosarcoma are sporadic; however, the disease can be associated with familial syndromes. Rhabdomyosarcoma is classified into histologic subtypes: embryonal, alveolar, pleomorphic, spindle, and mixed-type. Embryonal is the most commonly occurring subtype and also has the best prognosis. The management approach is tailored to a patient's risk stratification. Two systems are used to characterize risk stratification for RMS: the Clinical Group or the Stage. Each system uses different factors to categorize patients according to risk, and most authorities use both to determine the most appropriate therapeutic approach. Currently, treatment is multimodal, combining surgery, when feasible, to completely remove the primary tumor and chemotherapy to control disease spread, even if no evidence of metastasis is present on imaging because most patients have been found to have micrometastasis in studies. Radiotherapy is used to treat most high and intermediate-risk patients as well. The survival of rhabdomyosarcoma patients has improved due to interprofessional collaboration, leading to advancements in diagnosis and management approaches. This activity for healthcare professionals is designed to enhance the learner's competence when managing rhabdomyosarcoma, equipping them with updated knowledge, skills, and strategies for timely diagnosis and effective interventions, as well as highlighting the role of interprofessional coordination of care, leading to better outcomes for patients and reduced morbidity.


UAN: JA4008338-0000-23-3982-H01-P

Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify the known histopathologies of rhabdomyosarcoma.

  • Delineate the recommended evaluation and diagnosis of rhabdomyosarcoma.

  • Differentiate the treatment options for each rhabdomyosarcoma risk group.

  • Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by rhabdomyosarcoma.

Pharmacy Activity Type:
Disease/Drug Therapy Related


Disclosures

StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Pharmacists: StatPearls, LLC designates this activity for a maximum of 1.50 ACPE credit(s). (UAN: JA4008338-0000-23-3982-H01-P ). Pharmacists should only claim credit commensurate with the extent of their participation in the activity.

Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.    
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.

If you have concerns regarding the CE/CME system, please contact support@statpearls.com.

Disclaimer

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Faculty may discuss investigational products or off-label uses of products regulated by the FDA. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls expressly disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Unapproved Uses of Drugs/Devices: In accordance with FDA requirements, the audience is advised that information presented in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Cancellation Policy: Please see the cancellation policy. StatPearls, LLC reserves the right to cancel any course due to unforeseen circumstances.

 

 
 

Reviews

Ali A. on 8/15/2021

Jennifer K. on 3/6/2022

Dr.Mallikarjun K. on 5/7/2022

Lloyd R. on 2/27/2023

cynthia s. on 6/15/2023

Unlimited Pharmacist CE

Stay up to date on the latest medical knowledge with 6673 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7924.5 hours of CE.

Single Activity

Take this single activity

$43.50 1 activity

6 Month Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$119 per half year per user

1 Year Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$199 per 1 year per user